| [1] 黄宗顺,于水莲,陶怡. 过氧化物酶体增殖物激活受体γ激动剂在骨代谢中作用的研究进展[J]. 中华风湿病学杂志,2013, 17(3):195-197.[2] Surh YJ, Na HK, Park JM, et al. 15-Deoxy-△12,14-prostaglandin J2, an electrophilic lipid mediator of anti-inflammatory and pro-resolving signaling[J]. Biochem Pharmacol,2011, 82(10):1335-1351.[3] Scher JU, Pillinger MH. 15d-PGJ2:the an anti-inflammatory prostaglandin?[J]. Clin Immunol,2005, 114(2):100-109.[4] Haworth O, Buckley CD. Resolving the problem of persistence in the switch from acute to chronic inflammation[J]. Proc Natl Acad Sci U S A,2007, 104(52):20647-20648.[5] 李文惠,刘喆. 15-脱氧-Δ12,14-前列腺素J2在脑缺血中的神经保护作用[J]. 国际脑血管病杂志,2011, 19(11):849-852.[6] Wang X, Wang Y, Zhao X, et al. Potential effects of peroxisome proliferator-activated receptor activator on LPS-induced lung injury in rats[J]. Pulm Pharmacol Ther,2009, 22(4):318-325.[7] Clemente-Napimoga JT, Moreira JA, Grillo R, et al. 15d-PGJ2-loaded in nanocapsules enhance the antinociceptive properties into rat temporomandibular hypernociception[J]. Life Sci,2012, 90(23/24):944-949.[8] Quinteiro MS, Napimoga MH, Mesquita KP, et al. The indirect antinociceptive mechanism of 15d-PGJ2 on rheumatoid arthritis-induced TMJ inflammatory pain in rats[J]. Eur J Pain,2012, 16(8):1106-1115.[9] Tsubouchi Y, Kawahito Y, Kohno M, et al. Feedback control of the arachidonate cascade in rheumatoid synoviocytes by 15-deoxy-Delta(12,14)-prostaglandin J2[J]. Biochem Biophys Res Commun,2001, 283(4):750-755.[10] Monroy MA, Opperman KK, Pucciarelli M, et al. THE PPARgamma ligand 15d-PGJ2 modulates macrophage activation after injury in a murine trauma model[J]. Shock,2007,28(2):186-191.[11] Scher JU, Pillinger MH. 15d-PGJ2:the anti-inflammatory prostaglandin[J]. Clin Immunol, 2005, 114(2):100-109.[12] Rajakariar R, Hilliard M, Lawrence T, et al. Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta1214 PGJ2[J]. Proc Natl Acad Sci U S A,2007, 104(52):20979-20984.[13] Mbalaviele G, Abu-Amer Y, Meng A, et al. Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation[J]. J Biol Chem, 2000, 275(19):14388-14393.[14] Hounoki H, Sugiyama E, Mohamed SG, et al. Activation of peroxisome proliferator-activated receptor gamma inhibits TNF-alpha-mediated osteoclast differentiation in human peripheral monocytes in part via suppression of monocyte chemoattractant protein-1 expression[J]. Bone, 2008, 42(4):765-774.[15] Napimoga MH, Demasi AP, Bossonaro JP, et al. Low doses of 15d-PGJ2 induce osteoblast activity in a PPAR-gamma independent manner[J]. Int Immunopharmacol, 2013,16(2):131-138.[16] Jung WK, Park IS, Park SJ, et al. The 15-deoxy-Delta12,14-prostaglandin J2 inhibits LPS-stimulated AKT and NF-kappaB activation and suppresses interleukin-6 in osteoblast-like cells MC3T3E-1[J]. Life Sci, 2009, 85(1/2):46-53.[17] Kansanen E, Kivelä AM, Levonen AL. Regulation of Nrf2-dependent gene expression by 15-deoxy-Delta12,14-prostaglandin J2[J]. Free Radic Biol Med, 2009, 47(9):1310-1317.[18] Kim J, Cha YN, Surh YJ. A protective role of nuclear factor-erythroid 2-related factor-2(Nrf2) in inflammatory disorders[J]. Mutat Res, 2010, 690(1/2):12-23.[19] Martin-De-Saavedra MD, Budni J, Cunha MP, et al. Nrf2 participates in depressive disorders through an anti-inflammatory mechanism[J]. Psychoneuroendocrinology, 2013, 38(10):2010-2022.[20] Itoh K, Mochizuki M, Ishii Y, et al. Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-Delta(12,14)-prostaglandin j(2)[J]. Mol Cell Biol, 2004, 24(1):36-45.[21] 胡静. 基质金属蛋白酶与牙周病变的关系[J]. 解剖学研究, 2011, 33(5):373-374, 384.[22] 孟焕新. 牙周病学[M]. 北京:人民卫生出版社,2009:118-121.[23] Alves C.Melo N, Fraceto L, et al. Effects of 15d-PGJ(2)-loaded poly(D,L-lactide-co-glycolide) nanocapsules on inflammation[J]. Br J Pharmacol, 2011, 162(3):623-632.[24] Lin TH, Tang CH, Wu K, et al. 15-deoxy-△12,14-prostaglandin-J2 and ciglitazone inhibit TNF-alpha-induced matrix metalloproteinase 13 production via the antagonism of NF-κB activation in human synovial fibroblasts[J]. J Cell Physiol, 2011, 226(12):3242-3250.[25] Fahmi H, Di Battista JA, Pelletier JP, et al. Peroxisome proliferator——activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes[J]. Arthritis Rheum, 2001, 44(3):595-607.[26] Sawano H, Haneda M, Sugimoto T, et al. 15-Deoxy-Delta12,14-prostaglandin J2 inhibits IL-1beta-induced cyclooxygenase-2 expression in mesangial cells[J]. Kidney Int, 2002, 61(6):1957-1967.[27] Fahmi H, Pelletier JP, Mineau F, et al. 15d-PGJ(2) is acting as a ‘dual agent’ on the regulation of COX-2 expression in human osteoarthritic chondrocytes[J]. Osteoarthritis Cartilage, 2002, 10(11):845-848.[28] Reyes-Martin P, Ramirez-Rubio S, Parra-Cid T, et al. 15-Deoxy-delta12,14-prostaglandin-J(2) up-regulates cyclooxygenase-2 but inhibits prostaglandin-E(2) production through a thiol antioxidant-sensitive mechanism[J]. Pharmacol Res, 2008, 57(5):344-350.[29] Napimoga MH, da Silva CA, Carregaro V, et al. Exogenous administration of 15d-PGJ2-loaded nanocapsules inhibits bone resorption in a mouse periodontitis model[J]. J Immunol, 2012, 189(2):1043-1052. |
